Protocol No
NEURO-INHIBIKASE-IKT-148009
Phase
II
Summary
This project is being done to learn more about how safe IkT-148009 is in patients with PD at 2 different doses. The objective is to identify the following:
- Minimum safe does
- Maximum safe tolerated dose
- Evaluate efficacy
Description
IkT-148009 in Untreated Parkinson's Disease
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
ClinicalTrials.gov